A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations

Phase 1 Completed 8 enrolled Aligos Therapeutics

RandomizedCrossoverOpen-labelTreatment

Summary

This is a phase 1 single dose, open-label, randomized, two-period, two-sequence, crossover study of ALG-055009 conducted in 1 cohort of healthy volunteers. The primary purpose of this study is to compare the single-dose pharmacokinetics of the 0.7 mg dose level of 2 types of soft gelatin capsule formulations of ALG-055009, Formulation 1 and Formulation 2, in approximately 8 healthy volunteers.

Timeline

Start: 2025-03-25
Primary completion: 2025-05-08
Completion: 2025-05-16

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ALG-055009	Unknown	0.7 mg	Oral

Indications

No indication recorded.